Back to Screener

Healthcare

Puma Biotechnology, Inc.(PBYI)

Live Price

Offline

$7.56

+4.56% today

1Y Change

+116.62%

Window

Jun 26, 2025 โ†’ Jun 16, 2026

Market Cap
$380.00M
Revenue Growth
-0.9%
EPS Growth
0.0%
Dividend Yield
0.0%

Coverage: 244 bars ยท Jun 26, 2025 โ†’ Jun 16, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Puma Biotechnology, Inc. (PBYI) is a Healthcare stock with a market cap of $380.00M and listed on NASDAQ. The stock last traded around $7.56 and up 116.6% across the available one-year price window (Jun 26, 2025 โ†’ Jun 16, 2026). Baseline metrics include revenue growth of -0.9%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue -0.9%, EPS 0.0%, free cash flow +7.4% with operating margin 16.3% and ROIC 20.4%. Valuation is more restrained than many high-expectation growth names at P/E 12.1 and price/sales 1.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PBYI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Benchmark Edge

PBYI vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

PBYI

โ€”

Normalized return

SPY

--

S&P 500

Excess Return

--

Relative to SPY

PBYI Max Drawdown

-25.78%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for PBYI and SPY.

Calendar-year return history is still loading or unavailable.

Unable to load analyst forecasts.

Timed out loading forecasts for PBYI

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.